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a face-to-face meeting was held to discuss and finalize the 
consensus results.
Results mpMRI should be performed in patients with prior 
negative biopsies if clinical suspicion remains, but not 
instead of the PSA test, nor as a stand-alone diagnostic tool 
or mpMRI-targeted biopsies only. It is not recommended to 
use a 1.5 Tesla MRI scanner without an endorectal or pelvic 
phased-array coil. mpMRI should be performed following 
standard biopsy-based PCa diagnosis in both the planning 
and follow-up of FT. If a lesion is seen, MRI-TRUS fusion 
biopsies should be performed for FT planning. System-
atic biopsies are still required for FT planning in biopsy-
naïve patients and for patients with residual PCa after FT. 
Abstract 
Purpose To codify the use of multiparametric magnetic 
resonance imaging (mpMRI) for the interrogation of pros-
tate neoplasia (PCa) in clinical practice and focal therapy 
(FT).
Methods An international collaborative consensus project 
was undertaken using the Delphi method among experts in 
the field of PCa. An online questionnaire was presented in 
three consecutive rounds and modified each round based 
on the comments provided by the experts. Subsequently, 
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Standard repeat biopsies should be taken during the follow-
up of FT. The final decision to perform FT should be based 
on histopathology. However, these consensus statements 
may differ for expert centers versus non-expert centers.
Conclusions The mpMRI is an important tool for char-
acterizing and targeting PCa in clinical practice and FT. 
Standardization of acquisition and reading should be the 
main priority to guarantee consistent mpMRI quality 
throughout the urological community.
Keywords Focal therapy · Prostate cancer · Consensus · 
Magnetic resonance imaging · Delphi
Introduction
Recent technological advancements in multiparametric 
magnetic resonance imaging (mpMRI) have resulted in 
improved detection of clinically significant prostate cancer 
(PCa) and are increasingly used in urological practice and 
for focal therapy (FT). MpMRI most commonly includes 
T1-2-weighted imaging, dynamic contrast-enhanced (DCE) 
and diffusion-weighted imaging (DWI), providing clini-
cians with meaningful information regarding lesion volume, 
morphology, location and disease extent. Dynamic three-
dimensional lesion characterization and risk assessment with 
mpMRI is key for adequate patient selection and treatment 
planning for FT. Clinical guidelines for standardized report-
ing and acquisition (e.g., PI-RADS v2 [1] or Likert scale) of 
prostate mpMRI are nowadays advised for both research and 
clinical practice. When comparing mpMRI and pathology 
following radical prostatectomy (sliced by use of a custom-
ized 3D mold), the positive predictive value (PPV) for the 
detection of PCa in the peripheral zone, central zone and 
overall prostate was 98, 100 and 98 %, respectively, whereas 
the negative predictive value (NPV) was 90 % for all mpMRI 
sequences [2]. In another series, the positive and negative 
predictive values were 86 and 85 % for lesions >0.2 mL 
and 77 and 95 % for lesions >0.5 mL [3]. Noteworthy, most 
excellent results on mpMRI PCa detection are published by 
expert centers where the quality of the mpMRI is assured by 
standardized acquisition, interpretation and image-pathology 
feedback. Hence, results may not be reflective to general 
urological practice (for an overview table on mpMRI PCa 
detection see [4, 5]). To illustrate, a recent systematic review 
of available literature on the detection of significant PCa by 
mpMRI showed that the NPV ranged from 63 to 98 % [6]; 
however, the majority of the included studies used prostate 
biopsies for histopathological validation.
Of interest for FT of the index lesion, the PPV of 
mpMRI was reported to be 82.6 % [7], whereas 80 % of 
all index tumors and 72 % of Gleason ≥7 tumors on whole 
mount pathology were identified by mpMRI [8]. Moreover, 
mpMRI-transrectal ultrasound (TRUS) fusion (cognitive 
and system-based) targeted biopsies (TB) has shown to 
decrease the detection of clinically insignificant PCa and 
increase de detection rate of clinically significant PCa with 
an absolute difference of 6.8 % between mpMRI-TRUS 
fusion TB versus TRUS-guided biopsies [9]. However, 
not all studies reached a statistically significant difference 
[9–15] (for systematic review see [9, 15]). Expert panels 
recommend to perform repeated mpMRI during surveil-
lance following FT [4]. MpMRI-TRUS fusion TB has been 
shown to increase the detection of clinically significant 
PCa in the follow-up during active surveillance or during 
confirmatory biopsies of patients with previous negative 
TRUS-guided biopsies [16–18]. With increasing evidence, 
the position of mpMRI and MR-targeted biopsies to the 
accepted standard of PCa diagnostics needs to be re-eval-
uated. Therefore, an international multidisciplinary consen-
sus project was initiated using the Delphi method, aiming 
to define the use of mpMRI and MR-targeted biopsies in 
clinical practice and focal therapy of PCa.
Methods
The Delphi method
This consensus project was executed following the Delphi 
method [19]. In short, a systematic literature search was 
conducted after which experts were selected and invited 
to participate. An online survey using online question-
naire software (www.SurveyMonkey.com) was constructed 
and presented to participants in three consecutive rounds. 
Only experts that completed all previous rounds were re-
invited to participate in the subsequent round. After each 
round, the questionnaire was modified based on the com-
ments provided by experts and aggregated results of the 
previous round were anonymously presented to allow the 
experts to re-evaluate their answers without peer-pressure. 
Subsequently, a face-to-face meeting was held to discuss 
the results of the online survey.
A systematic literature search of the PubMed database 
was performed on February 18, 2016 (see Fig. 1.), with 
filters: English language, full-text availability and human 
studies. Articles involving salvage therapy, reviews or small 
pilot-trials (n ≤ 10) were excluded. After reviewing the lit-
erature, 166 experts were invited to participate based on 
authorship or peer-recommendation. The online consensus 
process was performed between March 21 and May 27, 
2016. The percentage of unanimity that should be reached 
to reach consensus was set at 80 %. A face-to-face panel 
meeting was organized on June 23, 2016, during the 9th 
International Symposium on Focal Therapy and Imaging 
in Prostate and Kidney Cancer (www.focaltherapy.org) and 
World J Urol 
1 3
was attended by 17 participants (94 % completed all online 
rounds). Panelists discussed inconclusive results from the 
questionnaire in detail, as by definition results with online 
confirmed consensus cannot be changed. For an overview 
of the final results of the online questionnaire and face-to-
face panel outcomes, see in ESM 1.
Results
Consensus process and background of participants
Ninety experts (90/166) accepted the invitation, and the 
response rate for the questionnaire was 100 % (90/90), 
94 % (85/90), 88 % (79/90) for rounds 1, 2, and 3, respec-
tively, and 87 % (78/90) completed all three rounds. In this 
group of experts 72 % were urologists, 16 % radiologists, 
3 % pathologists, 3 % radiation oncologists and 6 % sci-
entists. Average clinical experience in the field of PCa was 
18.9 years (SD 9.6), 1567 years in total, and include experi-
ence with the following focal ablative modalities (primary 
and/or salvage); cryosurgery (n = 11), high-intensity 
focused ultrasound (n = 22), irreversible electroporation 
(n = 11), laser therapy (n = 5), vascular-targeted photody-
namic therapy (n = 8), other (n = 4) and not specified/no 
FT (n = 29). Some participants had experience with more 
than one ablative modality for FT. A MRI-TRUS fusion 
system is used by 83 % (64/77) of clinicians in clinical 
practice to guide prostate biopsies or focal treatment pro-
cedures. A standardized mpMRI protocol (85 % PI-RADS, 
7 % Likert, 2 % both PI-RADS/Likert, 2 % other) is used 
by 96 % (79/82) of clinicians. In conclusion, this group 
may provide a valid expert opinion due to the aforemen-
tioned experience of the participants with the utility of 
mpMRI and targeted biopsies in both clinical practice and 
focal therapy of PCa. For a list of all participants of the 
online survey and panel meeting, see in ESM 2.
mpMRI in clinical urological practice
It is not recommended to use a 1.5 Tesla MRI scanner without 
an endorectal coil (ERC) or pelvic phased-array coil (81 % of 
Fig. 1  Systematic literature search
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whole group against, 92 % of radiologist against) and 83 % 
of the radiologists were also against the use of a 1.5T with 
a pelvic phased-array coil only. The panel emphasized that 
with older 1.5T systems, the use of an ERC is indispensable. 
When, however, newer generation 1.5T systems are used and/
or if an experienced radiologist optimizes other acquisition 
parameters, good image quality can be obtained with 1.5T 
scanners without the use of an ERC. This is in line with the 
recommendations of the PI-RADS Steering Committee [1].
The use of mpMRI in the workup for patients suspected 
of PCa was codified, and consensus was reached that 
mpMRI should be performed after the first set of negative 
TRUS-guided biopsies if clinical suspicion remains (90 %), 
but not instead of the PSA test (96 %) nor as stand-alone 
diagnostic tool (95 %) or TB only (76 % with panel agree-
ment). There was no agreement on whether or not mpMRI 
should be performed in the workup for all patients with 
suspicion of PCa, in combination with standard (10–12 
core) prostate biopsies and mpMRI-TRUS fusion TB (if 
lesion is seen). The panel stated that only in expert cent-
ers, where the quality is assured and their own results are 
monitored, mpMRI may be performed in all patients sus-
pected of PCa since it could increase the detection of clini-
cally significant PCa, reduce the need for repeat biopsies 
and may avoid prostate biopsies in patients with a negative 
mpMRI [20]. Therefore, it could be economically justifi-
able, however, adequate cost-benefit studies per health care 
system are lacking and should be performed.
The experts were divided on whether the current NPV 
of mpMRI is acceptable in clinical practice to rule out sig-
nificant PCa (47 % agree/49 % disagree). The panel refines 
that it may be applicable for expert centers with a known 
NPV of >90 % for clinically significant PCa, but not in 
community practice. In line, no consensus was reached 
that, after the first set of negative prostate biopsies, repeat 
prostate biopsies can be deferred if mpMRI does not show 
any suspect lesions. However, according to a recent AUA-
SAR consensus statement, deferral of repeat biopsy may be 
considered in expert centers in case of a negative mpMRI 
(without a strong clinical suspicion) [21].
If prostate biopsies are performed before mpMRI, the 
majority recommended the minimum acceptable interval 
to wait before performing mpMRI to be 6 weeks (68 % 
with panel agreement), although it would still impair the 
imaging quality (97 %). Literature shows that post biopsy 
hemorrhage was prevalent (57 %) within 6 weeks following 
prostate biopsies, but did not have a detrimental effect on 
tumor detection or staging [22, 23].
Focal therapy planning
MpMRI should be performed for FT planning in patients 
with a TRUS-guided biopsy confirmed PCa (94 %), 
including T1-2-weighted imaging, DCE and DWI, but 
without magnetic resonance spectroscopic imaging (MRSI) 
(83 %). MRI-TRUS fusion (either system or cognitive) is 
the recommended technique to perform biopsies follow-
ing mpMRI (93 %) if a radiographic lesion is seen and is 
deemed targetable. Transperineal template mapping biop-
sies (TTMB) (58 % in favor with panel agreement) can 
also be considered, whereas TRUS-guided and in bore MR-
guided biopsies are the least favorable techniques (58 and 
64 % against, respectively). The panel highlighted that all 
techniques can be considered, depending on availability 
and experience, but acknowledged MRI-TRUS fusion as 
the optimal approach. Stand-alone MRI-targeted prostate 
biopsies are only sufficient for FT planning without sys-
tematic (random) biopsies in patients with previous nega-
tive TTMB (86 %), but not in biopsy-naïve patients (93 %) 
or in patients undergoing repeat biopsies after primary FT 
for low- to intermediate-risk PCa (81 %). The final decision 
to perform FT should be based on (targeted) histopathology 
and should not be based on mpMRI results/PI-RADS score 
(86 %) alone. Histopathological confirmation remains cru-
cial since a recent prospective evaluation of the PI-RADS 
v2 found a relatively low cancer detection rate of 16, 30 
and 78 % for PI-RADS score 3, 4 and 5, respectively [24].
Precise Lesion size and extension cannot be adequately 
assessed based with the current mpMRI quality according 
to the available scientific data for focal treatment plan-
ning (82 %). In a small cohort (n = 33), it was shown 
that mpMRI underestimated lesion size and boundaries. 
This underestimation was larger for high suspicion on 
imaging or higher Gleason score, however, if a simulated 
safety margin of 9 mm was applied, all lesions would have 
been treated completely [25]. The panel agreed that more 
data are needed to optimize treatment boundaries for FT 
planning.
mpMRI during and in the follow‑up of focal therapy
MRI-TRUS system fusion is considered to be the best and 
most practical imaging modality to guide FT procedures 
(e.g., needle-placement) (86 % agreement). However, the 
panel remarked that cognitive fusion or other modalities 
might be acceptable, depending on availability and expe-
rience. MpMRI should be part of the follow-up (standard-
ized care) following focal therapy (91 %), excluding MRSI 
(79 %, with panel agreement). MRI-TRUS fusion biopsies 
should be performed following mpMRI if a lesion is seen 
(78 %, with panel agreement). To illustrate: in 59 patients 
suspected of recurrent PCa following HIFU, the likelihood 
of finding PCa was greater with TB on lesions seen with 
T2-weighted and DCE-MRI compared with systematic 
random biopsies [26]. However, mpMRI with MRI-TRUS 
fusion TB cannot serve as stand-alone follow-up modality 
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following FT and standard repeat (random) biopsies should 
be taken (78 %, with panel agreement). In a paper by Shah 
et al. on the histological outcomes after focal HIFU and 
focal cryosurgery, standard repeat biopsies were positive in 
25 % (98/391) and 22 % (39/175) for focal cryosurgery and 
focal HIFU, respectively [27]. The majority of these posi-
tive post-treatment biopsies were clinically insignificant 
PCa, and whether these lesions would have been identified 
by mpMRI remains unknown. To the best of our knowl-
edge, there are no large series comparing MR-guided TB 
with standard systematic repeat biopsies on their ability to 
detect clinically significant PCa following FT.
Discussion
This Delphi consensus project represents the opinion of 
90 FT experts, experienced with mpMRI and MRI-TRUS 
fusion (TB), for all recommendations see Table 1. Despite 
experience, it should still be regarded as expert opinion, 
considered level 5 evidence, may be biased by personal 
enthusiasm and is potentially not reflective for community-
based urologists. Nonetheless, these statements can provide 
clinicians guidance in areas where high-level evidence is 
sparse and provide a basis for standardization for clinical 
utilization of mpMRI and/or focal therapy that could result 
in improved interpretation of reported series.
The main challenge that was repeatedly encountered was 
the discrepancy regarding the consensus statements that can 
be made for expert centers versus non-expert centers. For 
experienced centers, where high-quality mpMRI is obtained 
by standardized reporting and acquisition, experience by radi-
ologists, and where the own data are known, some excellent 
results have been published, establishing the mpMRI as a 
reliable diagnostic tool [2, 3, 6]. In community practice, this 
process may be less optimal, causing heterogeneous mpMRI 
quality with decreased sensitivity and specificity, resulting 
in clinically significant PCa being missed, understaging and 
a high number needed to image impairing the potential cost-
effectiveness [20]. The panel argued that it should be our goal 
to guarantee high-quality mpMRI throughout the urologi-
cal community before implementing it as standard of care. 
Important elements to achieve this are expert training, imag-
ing-pathology feedback and/or certification. Moreover, cost-
benefit studies must be performed per health care system and 
the availability of MRI scanners and logistics should improve 
[28]. Furthermore, it may be inevitable that FT can only be 
performed in centers where the mpMRI quality is guaranteed, 
since mpMRI and MRI-TRUS fusion biopsies should be per-
formed in both the planning and follow-up of FT.
This consensus project recommended that mpMRI 
should be performed in patients with prior negative biop-
sies if clinical suspicion for PCa remains, which is stated 
more firmly than the EAU guideline recommendation that 
mpMRI may be used to evaluate the need to perform repeat 
biopsies [28]. Ahmed et al. presented during the 9th Inter-
national Symposium on Focal Therapy and Imaging in 
Prostate and Kidney Cancer the first level 1 evidence that 
using mpMRI as a triage test, in all patients suspected of 
PCa (n = 576), can avoid unnecessary prostate biopsies 
and detected more clinically significant PCa (≥Gleason 
4 + 3) than systematic (random) TRUS-guided biopsies. 
Based on their results, these authors calculated that in the 
United Kingdom it was cost-effective to perform mpMRI in 
all patients suspected of PCa (unpublished data, [20]). This 
underlines the panel statement that in expert centers mpMRI 
may be performed in all patients suspected of PCa. The 
outcomes regarding mpMRI acquisition and reporting are 
Table 1  Overview of consensus recommendations
Recommendation Online or panel agreement
mpMRI should be performed in patients with prior negative biopsies if clinical suspicion remains Online
mpMRI should not be performed as stand-alone diagnostic tool or with mpMRI-targeted biopsies only Online
mpMRI should be performed following standard biopsy-based PCa diagnosis in both the planning  
and follow-up of FT
Online
MRI-TRUS fusion is the recommended technique to perform biopsies following mpMRI Online
Systematic biopsies are still required for FT planning in biopsy-naïve patients and patients with  
residual PCa after FT
Online
Repeat biopsies should be taken during the follow-up of FT Online
The final decision to perform FT should be based on histopathology and not be based on mpMRI  
results alone
Online
Only in expert centers, where the quality is assured and own results are monitored, mpMRI may be  
performed in all patients suspected of PCa
Panel
Only in expert centers, deferral of repeat biopsy may be considered in case of a negative mpMRI Panel
It should be our goal to guarantee high-quality mpMRI throughout the urological community before implementing 
it as standard of care
Panel
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following the recommendations by the PI-RADS Steering 
Committee [1] that shows the potential that the PI-RADS 
recommendations have to effectuate uniform mpMRI.
Previous consensus meetings differed on the need for 
systematic biopsies when MRI-TRUS fusion TB were per-
formed in biopsy-naïve patients [29, 30]. Since mpMRI 
quality is not constant throughout the field, abandoning 
systematic biopsies after MRI-TRUS fusion TB for FT 
planning in biopsy-naïve patients is not recommended by 
this consensus group. In line, systematic prostate biopsies 
should be taken during the follow-up after FT.
Conclusions
In expert centers mpMRI evaluation of the prostate is 
an established component in PCa diagnostics and this 
consensus project aimed to define the use of mpMRI in 
clinical care, especially in relation to FT. In FT, mpMRI 
should be used for patient selection, treatment plan-
ning or guidance, and post-treatment monitoring. Newly 
developed MRI-TRUS (system or cognitive) fusion is 
increasingly being used either during prostate biopsy 
procedures or during treatment planning or guidance. 
This consensus project was conducted during the turn-
ing point whether or not mpMRI of the prostate should 
be standard of care in all patients with or suspected of 
PCa. Standardization of acquisition and reading should 
be the main priority to guarantee consistent mpMRI qual-
ity throughout the field to substantiate the discrepancy 
between what you want to recommend and what you 
actually can recommend.
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